All News

In this video, @rheumnow faculty recapped pre-ACR events, opening day lecture with @DrDavidKarp @DoctorYasmin year in review. #ACR21 @uptoTate @RHEUMarampa https://t.co/CO1uIyj1Z0 via @YouTube

ACR21 Opening Day Recap: Drs. Cush, Dao, Tate and Reyes - YouTube

Tyk2/Jak1 inhibitor brepocitinib in PsA. Looks good. Works for skin, joints, enthesitis, dactylitis, and PROs. No unexpected safety signals. Abstr#0488 #ACR21 @RheumNow https://t.co/MIOLw8BABN

Prolonging the Controversy of Hydroxychloroquine Dr. Kathryn Dao (@KDAO2011 ) shares several abstracts from #ACR21 that addressed the topic of HCQ and cardiovascular safety. https://t.co/J6sVzYJkUZ https://t.co/dBZmtwQ927

https://bit.ly/3wyEJTb

My first video for #ACR21 for @RheumNow, discussing #SickLeave, #WorkParticipation and #WorkDisability in patients with #SpA, with a focus on abstracts 0380 and 0381 by @ElenaNikiUK #axspa #spondyloarthritis #arthritis #qualityoflife Watch it here👇🏼 https://t.co/MEQ4wkFxrx

Sick Leave and Work Disability in Patients with AxSpA: Dr. Mrinalini Dey | Rheu…

#ACR21 #Abstr0252 Let's examine our patients than relying on tests. In sJIA pts presenting with fever, clinical features (fever pattern, rash and MSK symptoms) distinguished inflammation vs infection but not CRP, ferritin and procalcitonin @RheumNow https://t.co/s61WGBVK73 https://t.co/qhN95GdwgJ

Role of Clinical and Laboratory Parameters in Differentiating Infection from Di…

A key reason I'm looking forward to in-person conferences again, is so I don't have to perform the mental gymnastics and stress of ensuring I make all the sessions and meetings on time! 😂 ⏰UK colleagues- time difference for #ACR21 will be +5️hours from tomorrow! @RheumNow https://t.co/wl7ij3vyOU

American College of Rheumatology on Twitter: "#ACR21 Attendees – The Easte…

Top Influencers of #acr21: @ACRheum @rheum_cat @RheumNow @CreakyJoints @DoctorYasmin @KDAO2011 More 📊 https://t.co/vyMAwjKbqC

#acr21 - ACR Convergence 2021 - Social Media Analytics and Transcripts

There is a strong association with pre-ICI autoantibody positivity and any-type irAE development as well as high specificity of RF and CCP for ICI-arthritis. Prospective evaluation of RF/CCP pre-treatment may be useful @RheumNow #ACR21 Abst#0440 https://t.co/P7L7pL1iuV

Association Between Rheumatic Autoantibody Positivity and Immune-related Advers…

Excellent debate in #Lupus nephritis 6S214 with Wofsy, Isenberg & Costenbader. Q’s. What to do about Class V renal, many class III, IV LNdon’t go into sustained remission, cases of new onset LN in pts with #Belimumab ?more/less than expected, which drug to use @RheumNow #ACR21 https://t.co/tWbw79dE7d

Torgutalp et al. ⭐️Included Early axSpA - 166 nr-axSpA (symptom duration ≤5 y) and 135 with r-axSpA (symptom duration ≤10 y) from German Cohort ⭐️Assessed TNFI use over 2 years and has shown🔽 in radiographic sacroiliitis progression. Abst#0451 #ACR21 @RheumNow #ACRBest https://t.co/xP0wMLSyGw

RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.

IL-22 as a potential biomarker of AxSpA from non-inflammatory mimickers? ⬆️IL-22 in AxSpA vs. controls ⭐️IL-22 did not correlate w/ mSASSS, BASADI, ASDAS, CRP Abs#385 #ACR21 @RheumNow https://t.co/hNtStAluJH

#ACR21 #Abstr0189 Another case for early intervention. Median time-to-Rilonacept (IL1-i) monotherapy for recurrent pericarditis was 7.9 weeks! During this time, >94% pts discontinued steroid and/or colchicine either sequentially or concurrently @RheumNow https://t.co/ofi3Jtm6j6 https://t.co/b6PnFw4gUN

Tapering and Discontinuation of Background Therapies During the Transition to R…

Active RA w/ large joint swelling & co-existent CVD & diabetes associated with ⬆️risk of #AlzheimersDisease & related #dementia in RA pts. 👉~1300 patients 👉Among CVD conditions, #stroke & #CHF assoc w/ the risk of #dementia #ACR21 Abs#0284 @RheumNow https://t.co/N3x2ZtBFGe https://t.co/kFyf3A0gha

Risk Factors for Dementia in Patients with Incident Rheumatoid Arthritis: A Pop…

Risankizumab (IL-23i) KEEPsAKE 1 and 2 (phase 3) studies for PsA treatment ⬆️ACR20 response compared to pbo ⬆️secondary endpoints ⭐️no new safety signals Abs#453 #ACR21 #ACRBest @RheumNow https://t.co/7bwvIPMz38 https://t.co/TJaSqwipa5

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Int…

Abs 457 #ACR21 @rheumnow Exciting work by @alhkim and colleagues on SARS-CoV-2 Vaccination in CID patients - Most (90%) developed Ab response but with reduced titers - GC users including some low dose mounted low responses - TNFi reduced in vitro neutralization of delta variant https://t.co/fJxnKmbccc

Abs0266 #acr21 @RheumNow study of impact of pandemic on pts w/SLE (67%), RA (19%), & pSS (8%): 63%reported a flare since the pandemic & 16% had COVID-19. 19% reported no changes to their care.76% reported a change in their mood& emotional health. Was your pts experience similar?

2 year study of AxSpA pts in clinical remission who tapered TNFi. ⭐️52% successfully tapered to either 2/3, 1/2 or 1/3 dose ⭐️Baseline physician global score independent predictor of successful tapering Abs#364 #ACR21 @RheumNow https://t.co/9Kti5JGMYr https://t.co/y1Uj2dTABC

Dose Tapering of TNF Inhibitors in Patients with Axial Spondyloarthritis in Rou…

In a newly diagnosed SLE patient with class IV nephritis, already on HCQ, in addition to GC's, would you... #ACR21 #GreatDebate @rheumnow #LupusNephritis

#ACR21 #ACRBest @Rheumnow Abst #0452 Raychaudhuri et al. TB-PET/CT indices ➡️ disease outcome measures in PsA Identifies synovitis, enthesitis, dactylitis, nail matrix inflammation of PsA as compared to RA and OA Future use as a diagnostic tool for early disease of PsA https://t.co/uLsAWEkboS

Topics

All News

Do you get our email newsletter?